dm+d

Unassigned

New Medicines

DiamydType 1 diabetes mellitus treatment - intralymphatic injection

Information

Diamyd
New molecular entity
Diamyd Medical
Diamyd Medical

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
None

Category

A recombinant human glutamic acid decarboxylase 65 (GAD65) formulated with alum adjuvant. GAD65 is a major auto antigen in autoimmune diabetes, and is an enzyme that converts the excitatory neurotransmitter glutamate to the inhibitory transmitter GABA.
Currently, 3.8 million people in the UK are diagnosed with diabetes. Up to 1 million people have type 2 diabetes that is yet to be diagnosed, so the total is estimated to be 4.7 million people at present. This represents 7% of the UK population (1 in every 15 people) having diabetes (diagnosed and undiagnosed). 8% have type 1 diabetes [7]. Incidence is increasing by about 4% each year, particularly in children under five, with a 5% increase each year in this age group [2].
Type 1 diabetes mellitus treatment - intralymphatic injection
Intralymphatic injection
Parenteral